BDR Pharma gets DCGI nod for generic antibiotic drug Biapenem
Biapenem is a carbapenem used for treatment of moderate and severe bacterial infections.
New Delhi: BDR Pharmaceuticals on Friday said it has received approval from Drugs Controller General of India (DCGI) for its generic antibiotic drug Biapenem used for treatment of patients with intra-abdominal infections, lower respiratory infections, and complicated urinary tract infections.
The drug from the company in the form of an injection in 300mg strength will be available in the market shortly, BDR Pharmaceuticals said in a statement as reported by PTI.
"This drug will cover a broad spectrum of almost every infection and will be a great boon to the medical fraternity and patients," BDR Pharmaceuticals, Business Development - Director Raheel Shah said.
Biapenem is a carbapenem used for treatment of moderate and severe bacterial infections.
Medical Dialogues team had earlier reported that BDR Pharmaceuticals had launched generic Cabozantinib, used for the treatment of various types of cancer.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.